Dr. Vishwas (Vish) Seshadri, Ph.D., MBA, joined Abeona as SVP, Head of Research and Clinical Development in June 2021 and was appointed President, Chief Executive Officer and a director in October 2021. He has more than 20 years of experience across academia and senior life-sciences leadership roles spanning product development, regulatory submissions and commercialization of novel therapies, including personalized autologous cell and gene therapies. Before Abeona, from October 2010 to May 2021 he held roles of increasing responsibility at Celgene Corporation (now part of Bristol-Myers Squibb), most recently as Executive Director and Worldwide Brand Leader for Breyanzi (liso-cel), an autologous CD19-directed CAR T-cell therapy, and earlier led global project teams for REVLIMID, Abraxane, ISTODAX and other programs. He was previously Head of Early-Stage Upstream Process Development for Biologics at Dr. Reddy's Laboratories. Dr. Seshadri completed his Ph.D. in Microbiology, Immunology & Molecular Biology and a post-doc in epigenetics at the University of Arizona, and earned his MBA in Finance and Healthcare from the Wharton School of the University of Pennsylvania.